What are the treatment guidelines for acute decompensated heart failure?

Treatment Guidelines for Acute Decompensated Heart Failure

Initiate intravenous loop diuretics immediately as first-line therapy, with dosing of 20–40 mg IV furosemide for diuretic-naïve patients or at least the equivalent of the total daily oral dose for those already on chronic diuretics, while continuously monitoring urine output, renal function, and electrolytes. 1, 2

Initial Assessment and Hemodynamic Profiling

Before initiating therapy, rapidly assess the patient's hemodynamic profile to guide treatment decisions:

• Measure natriuretic peptides (BNP, NT-proBNP, or MR-proANP) in every patient presenting with acute dyspnea to differentiate heart failure from non-cardiac causes 2
• Perform immediate hemodynamic assessment including volume status (look for orthopnea, paroxysmal nocturnal dyspnea, bi-basilar rales, jugular venous distension, hepatojugular reflux, peripheral edema), perfusion adequacy (assess for cool extremities, altered mental status, oliguria), and blood pressure 1, 2
• Obtain 12-lead ECG and bedside echocardiography immediately when cardiogenic shock is suspected 2
• Check cardiac troponin levels to identify acute coronary syndrome as a precipitating factor 2

Diuretic Therapy (First-Line Treatment)

Initial Dosing Strategy

• For diuretic-naïve patients: Start with 20–40 mg IV furosemide (or equivalent loop diuretic) 1, 2
• For patients on chronic oral diuretics: Give an IV dose at least equivalent to the total daily oral dose 1, 2
• Administration method: Either intermittent boluses or continuous infusion is acceptable; adjust dose and duration according to clinical response 1, 2

Monitoring Requirements

• Continuously monitor symptoms, urine output, renal function, and electrolytes throughout IV diuretic therapy 1, 2
• Regularly reassess clinical status to guide dose adjustments 1

Management of Diuretic Resistance

When initial diuretic response is inadequate:

• First step: Increase the loop diuretic dose 2
• Second step: Add a thiazide-type diuretic (e.g., metolazone) or mineralocorticoid receptor antagonist (spironolactone) for refractory congestion 1, 2
• Third step: Consider ultrafiltration in patients with obvious volume overload or congestion that does not improve with optimized medical therapy 2

Vasodilator Therapy

IV vasodilators should be considered for symptomatic relief when systolic blood pressure >90 mmHg without symptomatic hypotension. 1, 2

Agent Selection and Indications

• In hypertensive acute heart failure: Initiate IV vasodilators (nitroglycerin, nitroprusside, or nesiritide) early as initial therapy to improve symptoms and reduce congestion 1, 2
• For acute coronary syndrome or flash pulmonary edema: Nitroglycerin is the preferred agent 2
• Monitor blood pressure and clinical symptoms frequently during vasodilator infusion 1, 2

Respiratory Support

Apply non-invasive positive-pressure ventilation (CPAP or pressure-support with PEEP) to reduce respiratory distress and potentially lower intubation rates. 1, 2

Pre-Hospital and Early Hospital Management

• CPAP can be safely delivered in pre-hospital settings because of its simplicity and minimal training requirements 1, 2
• On hospital arrival: Use pressure-support with PEEP for patients with persistent distress, especially when acidosis, hypercapnia, or chronic obstructive pulmonary disease are present 1, 2
• Oxygen therapy: Adjust FiO₂ up to 100% as needed to meet SpO₂ targets, while avoiding hyperoxia 1, 2

Intubation Considerations

• If intubation is required: Prefer midazolam over propofol for procedural sedation because propofol can induce hypotension and has cardiodepressive side effects, while midazolam has fewer cardiac side effects 1, 2

Inotropic Support (Restricted Use)

Inotropes are NOT recommended unless the patient is symptomatic hypotensive (SBP <90 mmHg) or shows evidence of hypoperfusion, due to safety concerns including increased mortality risk. 1, 2

When Inotropes Are Indicated

• Short-term IV inotropes (dobutamine, dopamine, levosimendan, or phosphodiesterase-III inhibitors) may be used to maintain systemic perfusion and end-organ function in hypotensive patients 1, 2
• Levosimendan or phosphodiesterase-III inhibitors can be considered to counteract beta-blockade-related hypotension 1, 2
• Continuous ECG and arterial blood-pressure monitoring is required because of the risk of arrhythmia, myocardial ischemia, and further hypotension 2

Vasopressor Therapy

• In cardiogenic shock refractory to inotropes: Norepinephrine is the preferred vasopressor to increase blood pressure and vital organ perfusion 1, 2

Continuation of Guideline-Directed Medical Therapy (GDMT)

Continue evidence-based disease-modifying therapies (beta-blockers, ACE-inhibitors/ARBs, mineralocorticoid receptor antagonists) in patients with worsening chronic HFrEF unless there is hemodynamic instability. 2

Key Principles

• Do NOT discontinue GDMT for mild renal function decline or asymptomatic blood-pressure reductions 2
• Beta-blockers should be continued or reduced in dose at admission but should not typically be held 2
• Initiate GDMT during hospitalization after the patient achieves clinical stability, especially in newly diagnosed HFrEF 2

Cardiogenic Shock Management

Transfer patients rapidly to a tertiary center equipped with 24/7 cardiac catheterization and mechanical circulatory-support capabilities. 2

Immediate Actions

• Perform immediate ECG and echocardiography on arrival 2
• In the presence of acute coronary syndrome with inadequate systemic perfusion: Consider urgent cardiac catheterization and revascularization 2
• If medical therapy fails and the patient is a candidate for cardiac transplantation or destination left ventricular assist device: Consider mechanical circulatory support early, prior to the development of end-organ damage 2

Additional Supportive Measures

Thromboembolism Prophylaxis

• Provide thromboembolism prophylaxis (e.g., low-molecular-weight heparin) to all patients not already anticoagulated and without contraindications 2

Identify and Treat Precipitating Factors

• Address precipitating factors such as acute coronary syndrome, uncontrolled hypertension, arrhythmias, infections, medication non-adherence, anemia, and thyroid dysfunction 2
• Avoid drugs that exacerbate heart failure: including non-steroidal anti-inflammatory drugs, COX-2 inhibitors, and thiazolidinediones 2

Common Pitfalls to Avoid

• Do NOT use inotropes in normotensive patients lacking evidence of organ hypoperfusion 1, 2
• Routine invasive hemodynamic monitoring is unnecessary in normotensive patients who respond to diuretics and vasodilators 2
• Do NOT discontinue GDMT prematurely for minor blood-pressure or renal-function changes 2
• Avoid hyperoxia despite the need for supplemental oxygen 1, 2